Back to Media Coverage

FDA OKS CHANGES FOR INSIGHTEC'S EXABLATE staff writers | October 9, 2015
icons for web-03.png

MR-guided focused ultrasound (MRgFUS) developer INSIGHTEC has received U.S. Food and Drug Administration (FDA) clearance for a new version of its ExAblate device and a change in labeling.


The new version of system is cleared for the treatment of symptomatic uterine fibroids, and with the updated labeling, fibroid tissue ablation can now be considered for patients who wish to retain fertility, the company said.


Read more

Media Contacts:

Please fill in the following details and we will get in touch with you. (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2018 INSIGHTEC Ltd. All rights reserved.

NGSoft logo